

Research

Open Access

## CXCR2 is critical for dsRNA-induced lung injury: relevance to viral lung infection

Vedang A Londhe<sup>1</sup>, John A Belperio<sup>2</sup>, Michael P Keane<sup>2</sup>, Marie D Burdick<sup>2</sup>, Ying Ying Xue<sup>2</sup> and Robert M Strieter\*<sup>1,2,3</sup>

Address: <sup>1</sup>Department of Pediatrics, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA, <sup>2</sup>Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA and <sup>3</sup>Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA

Email: Vedang A Londhe - vlondhe@mednet.ucla.edu; John A Belperio - jbelperio@mednet.ucla.edu; Michael P Keane - mkeane@mednet.ucla.edu; Marie D Burdick - mburdick@mednet.ucla.edu; Ying Ying Xue - yyxue@mednet.ucla.edu; Robert M Strieter\* - rstrieter@mednet.ucla.edu

\* Corresponding author

Published: 28 May 2005

Received: 02 December 2004

*Journal of Inflammation* 2005, 2:4 doi:10.1186/1476-9255-2-4

Accepted: 28 May 2005

This article is available from: <http://www.journal-inflammation.com/content/2/1/4>

© 2005 Londhe et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

### Abstract

**Background:** Respiratory viral infections are characterized by the infiltration of leukocytes, including activated neutrophils into the lung that can lead to sustained lung injury and potentially contribute to chronic lung disease. Specific mechanisms recruiting neutrophils to the lung during virus-induced lung inflammation and injury have not been fully elucidated. Since CXCL1 and CXCL2/3, acting through CXCR2, are potent neutrophil chemoattractants, we investigated their role in dsRNA-induced lung injury, where dsRNA (Poly IC) is a well-described synthetic agent mimicking acute viral infection.

**Methods:** We used 6–8 week old female BALB/c mice to intratracheally inject either single-stranded (ssRNA) or double-stranded RNA (dsRNA) into the airways. The lungs were then harvested at designated timepoints to characterize the elicited chemokine response and resultant lung injury following dsRNA exposure as demonstrated qualitatively by histopathologic analysis, and quantitatively by FACS, protein, and mRNA analysis of BAL fluid and tissue samples. We then repeated the experiments by first pretreating mice with an anti-PMN or corresponding control antibody, and then subsequently pretreating a separate cohort of mice with an anti-CXCR2 or corresponding control antibody prior to dsRNA exposure.

**Results:** Intratracheal dsRNA led to significant increases in neutrophil infiltration and lung injury in BALB/c mice at 72 h following dsRNA, but not in response to ssRNA (Poly C; control) treatment. Expression of CXCR2 ligands and CXCR2 paralleled neutrophil recruitment to the lung. Neutrophil depletion studies significantly reduced neutrophil infiltration and lung injury in response to dsRNA when mice were pretreated with an anti-PMN monoclonal Ab. Furthermore, inhibition of CXCR2 ligands/CXCR2 interaction by pretreating dsRNA-exposed mice with an anti-CXCR2 neutralizing Ab also significantly attenuated neutrophil sequestration and lung injury.

**Conclusion:** These findings demonstrate that CXC chemokine ligand/CXCR2 biological axis is critical during the pathogenesis of dsRNA-induced lung injury relevant to acute viral infections.

## Background

Viral infections of the respiratory tract are a cause of the common cold and flu in children and adults. These infections may predispose certain patients to develop chronic respiratory disorders such as asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, and bronchopulmonary dysplasia (BPD) [1]. Clinical symptoms include mucus secretion and altered airway reactivity and are hallmarked by the recruitment of inflammatory cells with resultant changes to the airway epithelial cell lining. Inflammation can also extend further into the lung to cause parenchymal disease that is characteristic of viral pneumonia as has been observed recently in severe acute respiratory syndrome (SARS) [2]. Inflammatory cell recruitment in large part is elicited by the generation of chemokines (chemotactic cytokines) that are also important in establishing a pro-inflammatory environment underlying chronic respiratory disorders such as asthma, COPD, cystic fibrosis, pulmonary fibrosis, and BPD [1,3-10].

Inflammatory changes due to viral infection result from the host immune response rather than secondary to viral replication or the viral particles themselves [11-15]. Viral infections of epithelial cells are characterized by the generation of the pro-inflammatory molecule double-stranded RNA (dsRNA) during intracellular replication of viruses. When studied in human epithelial cell lines *in vitro*, dsRNA triggers an innate immune response in host cells via generation of cytokines and chemokines involved in inflammatory cell recruitment. Specifically, dsRNA has been shown to induce activation of the neutrophil chemoattractant, interleukin-8 (IL-8/CXCL8), and regulated on activation, normal T cells expressed and secreted (RANTES) [16]. In human subjects *in vivo*, elevated tracheal IL-8/CXCL8 levels and neutrophil accumulation are found in airways of patients with asthma, COPD, and viral infection. While animal models *in vivo* have largely studied the systemic effects of intraperitoneal dsRNA treatment [17], there is a paucity of information on characterization and role of chemokines in lung inflammation and injury following intratracheal dsRNA instillation.

Murine KC/CXCL1 and MIP-2/CXCL2/3 are Glutamic acid-Leucine-Arginine-positive (ELR-positive) CXC chemokines; are structural homologs of human GRO- $\alpha$ /CXCL1 and GRO- $\beta/\gamma$ /CXCL2/3, respectively; and are functional homologs of human CXC chemokines, such as IL-8/CXCL8, ENA-78/CXCL5, and GRO- $\alpha/\beta/\gamma$ /CXCL1/2/3 [18-21]. Both murine chemokines share the ability to signal through a G protein-coupled receptor, CXCR2 [18-20]. Their human structural and functional homologs have been associated with asthma, COPD, and viral infections of the lung [22,23].

In the current study, we hypothesized that the early inflammation and resultant lung injury from intratracheal dsRNA treatment is due, in part, to the expression of ELR-positive CXC chemokines through their interaction with their major receptor, CXCR2. To test this hypothesis, we injected dsRNA intratracheally into 6–8 week old female BALB/c mice to measure neutrophil and chemokine responses and resultant injury in the airway and lung tissue compartments. We then blocked this response by pre-treating animals with antibodies to specifically neutralize neutrophil recruitment in a chemokine-dependent manner and thereby decreased lung inflammation and injury. Our animal model demonstrates the critical role of CXCR2 ligands/CXCR2 in acute lung inflammation and injury due to intratracheal dsRNA.

## Methods

### Reagents

RNA instillation: Double-stranded RNA (dsRNA, Poly IC) and single-stranded RNA (ssRNA, Poly C) were purchased from Sigma-Aldrich Corp. (St. Louis, Mo.) and reconstituted in sterile normal saline (20  $\mu$ g/ $\mu$ l) and stored at 4 °C prior to use.

### Enzyme-linked immunoadsorption assay (ELISA) experiments

Capture and Detection antibodies to murine KC/CXCL1 and murine MIP-2/CXCL2/3 were purchased as DuoSet<sup>®</sup> from R&D Systems (Minneapolis, MN).

Neutralization studies: Purified rat anti-mouse Ly-6G (Gr-1) mAb (clone RB6-8C5) was purchased from BD Pharmingen (San Diego, CA) and was used for neutrophil depletion studies as previously described [24]. Polyclonal goat anti-murine CXCR2 was produced by the immunization of a goat with a peptide containing the ligand-binding sequence Met-Gly-Glu-Phe-Lys-Val-Asp-Lys-Phe-Asn-Ile-Glu-Asp-Phe-Phe-Ser-Gly of CXCR2 [24-31]. The goat was immunized with CXCR2 in multiple intradermal sites with complete Freund's adjuvant (CFA) followed by at least 3 boosts of CXCR2 in incomplete Freund's adjuvant (IFA) as previously described. [24-31]. Direct ELISA was used to evaluate antisera titers, and sera was used for Western blot, ELISA and neutralization assays when titers had reached greater than 1/1,000,000. The CXCR2 protein sequence has been shown to contain the ligand-binding portion of the CXCR2 receptor [24-26,32]. The anti-CXCR2 antibodies have been used previously to block mouse CXCR2 *in vivo*, and has been shown to detect CXCR2 by Western blot and fluorescence-activated cell sorting analysis of neutrophils *in vivo* [24-26,32]. The anti-CXCR2 antibody has been shown to be neutralizing using both *in vitro* neutrophil chemotaxis assay and *in vivo* by abrogating the influx of neutrophils into the peritoneum of normal mice in response to exogenous ELR-positive murine CXC chemokines [24-26,32]. *In vivo*

administration of anti-CXCR2 antibodies inhibited pulmonary neutrophil sequestration in murine models of Aspergillosis, Nocardia, and Pseudomonas pneumonia and prevented the influx of neutrophils in urine and the kidney in a murine model of Escherichia coli urinary tract infection [24-26,32]. Moreover, intraperitoneal administration of this antibody did not alter peripheral blood neutrophil counts [24-26,32]. 1 ml of antiserum against mCXCR2 and control antibody is approximately 10 mg of IgG.

#### **Murine model of dsRNA-induced lung injury**

We used 6–8 week old female BALB/c mice to intratracheally inject either single-stranded (ssRNA) or double-stranded RNA (dsRNA) using a modification of a previously described method [30,33-36]. Mice were anesthetized with ketamine (60 mg/kg) intraperitoneally; then, under sterile conditions, the anterior neck soft tissue was dissected to expose the trachea and 50  $\mu$ l RNA (20  $\mu$ g/ $\mu$ l; 40  $\mu$ g/g mouse wt) was injected via 26 gauge tuberculin needle and syringe attached to a Stepper<sup>®</sup> microinjector (Indicon, Inc., Brookfield, CT) into the trachea under direct visualization. Immediately following the instillation, the skin was apposed and closed using tissue adhesive and the mice were allowed to recover from anesthesia prior to replacement into their cages.

In separate experiments, animals received either 1 ml of goat polyclonal anti-murine CXCR2, 1 ml of normal goat serum (NGS) control antibody, or 0.5 ml rat anti-mouse Ly-6G mAb or corresponding control intraperitoneally 24 hours before intratracheal injection and daily until time of sacrifice as previously described [37].

#### **Lung bronchoalveolar lavage and tissue preparation**

At time of sacrifice, 72 h following intratracheal dsRNA or ssRNA treatment, mice were euthanized using intraperitoneal Pentobarbital (100 mg/kg) and a heparinized sample of blood was harvested. The thoracic cavity was then exposed and lungs were perfused free of blood with 1 ml 0.9% normal saline via the spontaneously beating right ventricle under constant pressure of 25 cm H<sub>2</sub>O. A 26 gauge butterfly needle was used to cannulate the trachea and bronchoalveolar lavage (BAL) was performed by instilling 1 ml PBS + 5 mM EDTA solution as previously described [38]. Lungs were lavaged under constant pressure of 25 cm H<sub>2</sub>O and retrieved solutions were centrifuged at 900  $\times$  g for 15 min. The cell-free supernatants were assayed by specific ELISAs and collected cells were analyzed for total cell counts and cytospin differentials. Lung tissue was then processed for the following: calculation of lung edema; microvascular permeability; mRNA; ELISA analysis; and histopathological and immunohistochemical analysis by fixing in 4% paraformaldehyde at 25 to 30 cm H<sub>2</sub>O pressure and embedding in paraffin.

#### **Immunolocalization of TLR3**

Paraffin-embedded tissues from dsRNA-treated and ssRNA-treated lungs were processed for immunohistochemical localization of Toll-like receptor 3 (TLR3) expression using a method previously described [33,39]. Briefly, tissue sections were dewaxed with xylene and rehydrated through graded concentrations of ethanol. Tissue nonspecific binding sites were blocked using Power Block<sup>®</sup> (BioGenex, San Ramon, CA). Tissue sections were overlaid with 1:50 dilution of either control (goat) or polyclonal goat anti-TLR3 antibody (Santa Cruz Biotechnology Inc., Santa Cruz, CA). The tissue sections were washed with TRIS-buffered saline and then incubated for 60 min with secondary biotinylated antibody. The tissue sections were then washed in TRIS-buffered saline and incubated with alkaline phosphatase conjugated to streptavidin (BioGenex). Tissue sections were then incubated with Vectastain ABC reagent (Vector Laboratories, Burlingame, CA) followed by the peroxidase substrate, DAB reagent (Vector Laboratories). After optimal color development, tissue sections were immersed in sterile water, counterstained with Lerner's hematoxylin, and cover slipped using an aqueous mounting solution.

#### **Total RNA isolation and real-time quantitative PCR**

Total cellular RNA from lung tissue was isolated as previously described [30,31]. Total RNA was determined and 1  $\mu$ g of total RNA was reversed transcribed into cDNA and amplified using TaqMan Gene Expression Quantification assays (Applied Biosystems (Foster City, CA) Kit 4304134). cDNA was amplified and quantified using the TaqMan 7700 Sequence Detection System and specific primers for murine CXCL1, murine CXCL2/3, murine CXCR2 and a housekeeping gene 18S. The primers used were 5'-TGA-GCT-GCG-CTG-TCA-GTG-CCT-3' (sense) and 5'-AGA-AGC-CAG-CGT-TCA-CCA-GA-3' (antisense) for CXCL1 (259 bp) and 5'-GCT-GGC-CAC-CAA-CCA-CCA-GG-3' (sense) and 5'-AGC-GAG-GCA-CAT-CAG-GTA-CG-3' (antisense) for murine CXCL2/3 (359 bp). Predeveloped assay reagents (Applied Biosystems Kit 4304134) were used for murine CXCR2 and the housekeeping gene, 18S. Quantitative analysis of gene expression was done using the comparative C<sub>T</sub> ( $\Delta$ C<sub>T</sub>) methods, in which C<sub>T</sub> is the threshold cycle number (the minimum number of cycles needed before the product can be detected) [40,41]. The arithmetic formula for the  $\Delta$ C<sub>T</sub> method is the difference in threshold cycles for a target, (i.e., CXCR2) and an endogenous reference (i.e., housekeeping gene 18S). The amount of target normalized to an endogenous reference (i.e., CXCR2 in dsRNA-treated animals) and relative to a calibration normalized to an endogenous reference (i.e., CXCR2 in ssRNA-treated controls) is given by  $2^{-\Delta\Delta C_T}$  [40,41]. The following is an example for comparing CXCR2 expression from dsRNA-treated animals and ssRNA-treated controls. Both CXCR2 from

dsRNA-treated and ssRNA-treated controls are normalized to 18S:  $\Delta\Delta C_T = \Delta C_T$  (CXCR2 expression from dsRNA-treated animals normalized to endogenous 18S) -  $\Delta C_T$  (CXCR2 expression from ssRNA-treated controls normalized to endogenous 18S). The calculation of  $2^{-\Delta\Delta C_T}$  then gives a relative value when comparing the target with the calibrator, which we designate in this context as fold increase of dsRNA-treated animals to ssRNA-treated controls of the target mRNA relative quantification.

#### **Evans blue microvascular permeability and wet:dry analysis of lung edema**

Microvascular permeability related to lung injury was measured using a modification of the Evans blue dye extravasation technique, as previously described [30,42]. Extravasation of Evans blue (Sigma-Aldrich) into the extravascular compartment was used as a quantitative measure of lung injury and changes in microvasculature permeability. Briefly, each animal received 20 mg/kg Evans blue (pH 7.34) by tail vein injection 3 h before sacrifice. At the time of sacrifice, a heparinized sample of blood was harvested, and plasma was removed by centrifugation. Six lungs from each group were perfused free of blood with 1 ml 0.9% normal saline via the spontaneously beating right ventricle and removed from the thoracic cavity. The trachea, mainstem bronchi, and surrounding mediastinal structures were removed. Evans blue was extracted from pulmonary tissues after homogenization in 1 ml of 0.9% normal saline. This volume was added to 2 vol of deionized formamide and incubated at 60°C for 12 h. The supernatant was separated by centrifugation at  $2000 \times G$  for 30 min. Evans blue in the plasma and lung tissue was quantitated by dual-wavelength spectrophotometric analysis at 620 and 740 nm [43]. This method corrects the specimen's absorbance at 620 nm for the absorbance of contaminating heme pigments, using the following formula: corrected absorbance at 620 nm = actual absorbance at 620 nm - (1.426(absorbance at 740) + 0.03). We calculated a permeability index by dividing the correct pulmonary plasma Evans blue absorbance at 620 nm; this index reflects the degree of extravasation of Evans blue into the extravascular pulmonary tissue compartment.

To quantitate lung edema following dsRNA treatment, wet to dry weight ratios were obtained by ligating the lungs away from the hilum as previously described [40]. The lungs were blotted dry and weighed. They were then desiccated by incubation at 130°C overnight in a vacuum oven and re-weighed to determine their dry weight. The wet to dry ratio was then calculated.

#### **KC/CXCL1 and MIP-2/CXCL2/3 ELISAs**

KC/CXCL1 or MIP-2/CXCL2/3 protein was quantitated using a modification of a double ligand method as previ-

ously described [30,31,40,41]. Briefly, flat-bottomed 96 well microtiter plates (Nunc Immuno-Plate I 96-F) were coated with 50  $\mu$ l/well of capture antibody to murine KC/CXCL1 or MIP-2/CXCL2/3 (2  $\mu$ g/ml in sterile phosphate buffered saline (PBS), for 12 hrs at room temperature and then washed with phosphate buffered saline (PBS), pH 7.5, 0.05% Tween-20 (wash buffer). Microtiter plate non-specific binding sites were blocked with 2% BSA in PBS and incubated for 60 minutes at 37°C. Plates were washed three times with wash buffer and samples or standard were added, followed by incubation for 1 hour at 37°C. Plates were washed three times and 50  $\mu$ l/well of detection antibody for murine KC/CXCL1 and MIP-2/CXCL2/3 antibodies added, and plates were incubated for 45 minutes at 37°C. Plates were washed three times, streptavidin-peroxidase conjugate (Jackson Laboratories, West Grove, PA) added, and the plates incubated for 30 minutes at 37°C. Plates were washed three times and TMB (3,3',5,5'-tetramethylbenzidine) chromogen substrate (Kirkegaard & Perry Laboratories, Gaithersburg, MD) added. The plates were incubated at room temperature to the desired extinction, and the reaction terminated with 3 M H<sub>2</sub>SO<sub>4</sub> solution. Plates were read at 450 nm in an automated microplate reader (Bio-Tek Instruments, Inc., Winooski, VT). Standards were 1/2-log dilutions of either KC/CXCL1 or MIP-2/CXCL2/3 from 100 ng to 1 pg/ml (50  $\mu$ l/well). This ELISA method consistently detected specific chemokine concentrations in a linear fashion greater than 50 pg/ml. KC/CXCL1 and MIP-2/CXCL2/3 were specific in our sandwich ELISA without cross-reactivity to a panel of cytokines including murine C10, JE, MIP-1 $\alpha$ , MIP-1 $\beta$ , human GRO $\alpha$ , GRO $\beta$ , GRO $\gamma$ , RANTES, and members of the CXC and CC chemokine families.

#### **FACS analysis of lung neutrophils**

Whole lung single cell suspensions were made from harvested lungs from four mice per group using a method, as previously described [40]. Single cell suspensions ( $5 \times 10^6$  cells/ml) were stained with Abs: Tricolor-conjugated (BD Biosciences, Franklin Lakes, NJ) anti-murine CD45 (Caltag Laboratories, South San Francisco, CA), FITC-conjugated anti-murine MOMA-2 (macrophage surface marker; Seratec, Raleigh, NC), R-Phycoerythrin (R-PE) conjugated Rat anti-murine Ly-6G (neutrophil surface marker) and R-PE-conjugated mouse anti-murine CD3e (lymphocyte surface marker) (BD Biosciences). Dual-color-stained cell suspensions were analyzed on a FACS-can flow cytometer (Becton Dickinson Immunocytometry Systems, San Jose, CA) using CellQuest 3.2.1f1 software (BD Immunocytometry Systems).

#### **Statistical analysis**

Data were analyzed using the Microsoft® Excel 2000 statistical package (Microsoft Corporation, USA). Two group comparisons were evaluated using the unpaired Students

*t* test. Three group comparisons were evaluated by the ANOVA test with the post hoc analysis (i.e. Bonferroni/Dunn). Data were expressed as mean  $\pm$  SEM.

## Results

### **DsRNA induces expression of TLR3 on airway epithelial cells**

Since *in vitro* studies in human epithelial cells have demonstrated that dsRNA induces the generation of chemokines involved in leukocyte recruitment, we performed *in vivo* studies using a murine model system of intratracheal dsRNA-induced inflammation and injury to mimic an acute viral infection and thus dissect the mechanisms related to this process. The putative receptor for dsRNA has been identified as Toll-like receptor 3 (TLR3), thus we first determined whether dsRNA treatment was associated with expression of TLR3. Immunolocalization using goat anti-murine TLR3 Ab showed markedly increased expression of TLR3 localized to the surface airway epithelium of dsRNA-treated lungs as compared to ssRNA-treated controls at 72 h. Specificity to TLR3 was demonstrated by lack of staining on control goat IgG-stained sections from both dsRNA and ssRNA-treated groups (Fig. 1).

### **DsRNA induces lung neutrophil infiltration**

Mice treated with intratracheal dsRNA were noted to have significant intraparenchymal and airway leukocyte infiltration at 72 h following treatment as compared to naïve and ssRNA-treated controls as demonstrated by histopathology (Fig. 2A). No significant differences in cellular infiltrates were noted among the histopathologic groups at earlier timepoints 4, 12, 24, and 48 h following dsRNA treatment (data not shown). FACS and BAL analysis at 72 h following dsRNA treatment specifically showed that dsRNA induced significant neutrophil recruitment compared to controls (Fig. 2B and 2C).

### **DsRNA induces increased lung injury**

To determine if the influx of neutrophils into lung airways and parenchyma results in lung injury, we measured two markers of lung injury to quantify changes in lung edema and lung vascular permeability. Results showed a significant increase in the wet:dry ratio in dsRNA-treated lungs as compared to controls at 72 h following dsRNA treatment (Fig. 3A). Similarly, measurement of the lung:plasma extravasation ratio of Evans blue dye also showed a significant increase in microvascular permeability in dsRNA-treated lungs as compared to controls (Fig. 3B).

### **Neutrophil depletion decreases dsRNA-induced lung inflammation and injury**

With the finding that an increase in lung neutrophils coincided with an increase in lung injury in dsRNA-treated lungs, we next attempted to determine if this was a causal

relationship by inducing neutropenia and measuring changes in lung neutrophil influx and lung injury. Mice were passively immunized with specific anti-mouse Ly-6G mAb or corresponding control at -24 h as well as 0, 24, and 48 h following dsRNA treatment. Lungs were harvested at 72 h and results showed that animals pretreated with neutrophil depleting mAb had a significant decrease in total neutrophil counts in both lung tissue and airways as compared to controls as reflected by FACS analysis and BAL (Fig. 4A and 4B). Importantly, BAL samples of animals pretreated with anti-mouse Ly-6G mAb antibody showed a specific reduction in neutrophil number but no reduction in monocyte numbers (data not shown). Furthermore, neutrophil depletion resulted in decreased lung microvascular permeability back to baseline values (Fig. 4C).





### **DsRNA induces elevated KC/CXCL1 and MIP-2/CXCL2/3 mRNA and protein levels**

Since neutrophil influx was shown to result in lung injury in dsRNA-treated lungs, we next identified which specific factors, such as chemokines, were responsible for neutrophil recruitment. We focused on the ELR+ chemokines KC/CXCL1 and MIP-2/CXCL2/3, which are known to have neutrophil chemoattractant properties. DsRNA treatment resulted in significant increases in lung KC/CXCL1 mRNA levels as well as in protein levels from whole lung homogenates and BAL when compared to controls (Fig. 5A, C, and 5E) at 72 h following dsRNA treatment. Similarly, mRNA levels and lung protein expression of MIP-2/CXCL2/3 were also significantly elevated with an increasing trend noted in BAL protein from dsRNA-treated lungs as compared to controls (Fig. 5B, D, and 5F). Levels of CXCR2 chemokine ligands at earlier timepoints showed only a small increase (two-fold) in the induction of KC/CXCL1 and MIP-2/CXCL2/3 as early as 4 h following dsRNA-exposure (data not shown), but the maximal increase (>ten-fold for KC/CXCL1 and >four-fold for MIP-2/CXCL2/3) occurred at 72 h following dsRNA-exposure.

### **DsRNA increases CXCR2 expression in lungs**

CXCR2 is the shared cellular receptor for the murine CXC chemokine ligands KC/CXCL1 and MIP-2/CXCL2/3 [18-20]. The finding of increased levels of KC/CXCL1 and MIP-2/CXCL2/3 associated with dsRNA-induced neutrophil sequestration and lung injury led us to evaluate the expression of CXCR2 mRNA in the lungs of these animals. Lung homogenates from dsRNA-treated animals had significantly increased CXCR2 mRNA expression as compared to controls (Fig. 6). The expression of CXCR2 mRNA paralleled its ligand expression, neutrophil sequestration, and lung injury at 72 h following dsRNA treatment (Figs. 2, 3, and 5).




**dsRNA; Control Ab****dsRNA; Anti-TLR3 Ab****ssRNA; Control Ab****ssRNA; Anti-TLR3 Ab****Figure 1**

DsRNA induces expression of TLR3 on airway epithelial cells. Immunohistochemistry of lungs at 72 h following ssRNA or dsRNA treatment. Slides were stained with either control goat IgG or anti-TLR3 Ab (100X) ( $n = 4$  mice per group).

***Inhibition of CXCR2 inhibits infiltration of neutrophils and attenuates dsRNA-induced lung injury***


To better understand the mechanism partly responsible for dsRNA-induced lung neutrophilia and injury, we determined whether inhibiting CXCR2 ligand interaction

with CXCR2 significantly decreased neutrophil recruitment during the pathogenesis of dsRNA-induced lung injury. Mice were passively immunized with specific neutralizing anti-murine CXCR2 or with control antibody at -24 h, as well as 0, 24, and 48 h following dsRNA



**Figure 2**

DsRNA induces lung neutrophil infiltration. **(A)** Histopathology of naïve lung and at 72 h following treatment with ssRNA or dsRNA. Representative photomicrographs with H & E staining (100X; n = 4 mice per group). **(B)** Total lung cells via FACS analysis of whole-lung single-cell suspensions at 72 h (n = 4 mice per group; \*p < 0.05). **(C)** Total cells via BAL fluid cell count at 72 h (n = 4 mice per group; \*p < 0.05).




**Figure 3**  
DsRNA induces lung injury. **(A)** Wet: Dry ratio at 72 h ( $n = 6$  mice per group;  $*p < 0.05$ ). **(B)** Evans blue permeability index at 72 h ( $n = 6$  mice per group;  $*p < 0.05$ ).

treatment. Lungs were harvested at 72 h and results showed that BAL neutrophil counts from animals that received anti-CXCR2 Ab were significantly reduced as compared to control animals that received normal goat serum (Fig. 7A). Furthermore, measurement of lung edema and lung microvascular permeability also showed significant decreases in wet:dry and Evans blue extravasation in mice treated with anti-CXCR2 compared to NGS-treated controls (Fig. 7B and 7C). Finally, histopathologic comparison of lung fields from anti-CXCR2 pretreated mice showed marked reduction in leukocytic infiltrate as compared to NGS-pretreated controls (Fig. 7D).

## Discussion


Respiratory viral infections are characterized by a two-component immune response comprised of an innate component that is fully functional before viral entry into




**Figure 4**  
Neutrophil depletion decreases dsRNA-induced lung inflammation and injury. **(A)** Total lung PMNs via FACS analysis of whole-lung single-cell suspensions at 72 h. ( $n = 4$  mice per group;  $*p < 0.05$ ). **(B)** Total PMNs via BAL fluid cell count at 72 h ( $n = 4$  mice per group;  $*p < 0.05$ ). **(C)** Evans blue permeability index at 72 h ( $n = 6$  mice per group;  $p < 0.05$ ). Mice were pretreated control Ab or anti-PMN Ab at times -24, 0, 24, and 48 h following IT dsRNA treatment.

the epithelium and an adaptive component that develops in response to the continued presence of the virus [1]. The innate or acute inflammatory component is associated with a predominance of infiltrating neutrophils. While many viral infections of the lung are self-limiting, the associated lung injury due to this initial event may be critical in establishing a pro-inflammatory environment underlying certain chronic respiratory disorders such as asthma, COPD, cystic fibrosis, pulmonary fibrosis, viral pneumonia, and bronchopulmonary dysplasia [1,3-10]. The host's inflammatory response to viral replication leads to pulmonary pathology hallmarked by leukocyte infiltrate and resultant microvascular leak that progresses to lung edema and the clinical signs of pneumonia. As the



**Figure 5**

DsRNA induces elevated KC/CXCL1 and MIP-2/CXCL2/3 mRNA and protein levels. **(A and B)** Quantitative levels of CXCL1 and CXCL2/3 mRNA, respectively, in naïve lung and at 72 h following treatment with ssRNA or dsRNA ( $n = 6$  mice per group;  $*p < 0.05$ ). **(C and D)** Quantitative levels of CXCL1 and CXCL2/3 protein, respectively, in the lungs at 72 h ( $n = 6$  mice per group;  $*p < 0.05$ ). **(E and F)** Quantitative levels of CXCL1 and CXCL2/3 protein, respectively, in BAL fluid at 72 h ( $n = 6$  mice per group;  $*p < 0.05$ ).



**Figure 6**

DsRNA increases CXCR2 expression in lungs. Quantitative real-time PCR was determined by TaqMan analysis for CXCR2 mRNA from naïve lung and at 72 h following ssRNA or dsRNA treatment ( $n = 6$  mice per group;  $*p < 0.05$ ).

lung injury persists or recurs with multiple subsequent viral infections, pulmonary vascular and airway remodeling may occur and eventually lead to development of airway hyper-reactivity and/or interstitial fibrosis [44]. Viral infections are mediated by dsRNA, a proinflammatory molecule generated during viral replication. DsRNA binds to its cell surface receptor, TLR3, and activates the production of downstream gene products, such as CXC chemokines. In this study, we hypothesized that the interaction between CXCR2 and ELR-positive CXC chemokines expressed during dsRNA-induced lung inflammation is critical in mediating neutrophil recruitment, a pivotal process required for dsRNA induced lung injury in viral infections.


Previous studies have demonstrated that mice exposed to a live virus via intranasal inoculation generate a systemic acute-phase response with maximal pulmonary chemokine response at one week that includes both CC and CXC chemokines and is mouse strain-dependent (response in BALB/c greater than in C57BL/6 mice) [45,46]. A similar study using intratracheal delivery of live virus also demonstrated marked pulmonary pathology including mucous cell metaplasia and airway epithelial remodeling [47]. Another study focusing specifically on the effects of intratracheal dsRNA at a low dose found similar systemic inflammatory effects but specific pulmonary effects only when dsRNA was delivered in conjunction with IFN $\gamma$  [48]. Finally, a recent study examined the effects of inhibiting the CC chemokine receptor, CCR1, during live-virus

exposure in mice and showed that mortality during pneumovirus infection was decreased [49]. The present study extends these findings by first determining the effects of high-dose intratracheal dsRNA alone on neutrophil recruitment and lung injury in BALB/c mice and then subsequently blocking these effects via inhibition of the CXC chemokine receptor, CXCR2.

To determine the effects of dsRNA *in vivo*, we first characterized our murine model by performing a time-course of dsRNA to observe histopathologic changes at 0, 4, 12, 24, 48 and 72 h following intratracheal dsRNA delivery. We used a maximal dose of dsRNA at 40  $\mu\text{g/g}$  mouse wt after initial studies at lower doses (4  $\mu\text{g/g}$  and 20  $\mu\text{g/g}$ ) showed minimal leukocytic infiltrate. Furthermore, we are aware of only one other publication that describes intratracheal dsRNA delivery that showed no effects when used alone at low concentration (10  $\mu\text{g/g}$ ) [48]. Histopathological analysis demonstrated a significantly increased leukocytic infiltrate at 72 h following intratracheal dsRNA as compared to earlier time points. We thus chose this observation as the basis to focus upon the 72 h timepoint. Other studies using administration of dsRNA in BALB/c mice *in vivo* have also shown a maximal innate immune response starting at 72 h following dsRNA exposure [50]. Further characterization at 72 h following intratracheal dsRNA showed that neutrophils were a predominant cell type and that there was an associated injury to alveolar-capillary membrane integrity as shown by increased lung edema and microvascular leak.

Having characterized the histopathological damage caused by intratracheal dsRNA, we then focused on the underlying mechanisms responsible for promoting the inflammation and subsequent lung injury. Our findings of a significant increase in neutrophil infiltration following dsRNA treatment are consistent with findings from previous studies using a live virus that also resulted in early neutrophil infiltration [47]. In order to determine whether neutrophil influx was causally linked to the lung injury observed in our system, we performed studies using a monoclonal antibody to the Ly6G antigen on the surface of mouse granulocytes to specifically deplete neutrophils. These results showed decreased numbers of lung neutrophils by FACS analysis and BAL as expected with no reduction in monocyte number, and also showed a decrease in lung microvascular leak and therefore decreased lung injury associated with decreased neutrophil recruitment. However, the molecular and cellular mechanisms involved in recruiting these neutrophils remained to be fully elucidated.

Elegant *in vitro* studies have demonstrated that dsRNA can induce IL-8 expression from human bronchial epithelial cells [16]. Furthermore, *in vivo* studies using live virus



**Figure 7**

Inhibition of CXCR2 inhibits dsRNA-induced neutrophil recruitment and attenuates dsRNA-induced lung injury. **(A)** Total cells via BAL fluid cell count at 72 h ( $n = 4$ ;  $*p < 0.05$ ). **(B)** Wet: Dry ratio at 72 h ( $n = 6$  mice per group;  $*p < 0.05$ ). **(C)** Evans blue permeability index at 72 h ( $n = 6$  mice per group;  $*p < 0.05$ ). **(D)** Histopathology of lungs at 72 h following dsRNA treatment. Representative photomicrographs with H & E staining (100X;  $n = 4$  mice per group). Mice were pretreated with normal goat serum (control Ab) or anti-CXCR2 Ab at times -24, 0, 24, and 48 h following IT dsRNA treatment.

have also demonstrated that CXC chemokines are generated during lung inflammation [45-47]. Having demonstrated that lung injury due to intratracheal dsRNA is dependent on neutrophil infiltration, we determined that CXCL1 and CXCL2/3 expression was significantly greater in the lungs of dsRNA-treated mice than in lungs of ssRNA-treated controls. Furthermore, expression of CXCR2 mRNA was similarly increased in parallel to the production of both CXCL1 and CXCL2/3 ligands and neutrophil sequestration during dsRNA-induced lung inflammation. Other studies of inflammatory diseases, such as ventilator-induced lung injury, pneumonia, and hyperoxia-induced lung injury have demonstrated the importance of CXCR2 expression and its role in neutrophil recruitment during the pathogenesis of these diseases [24,40,41,51]. Collectively, these studies demonstrate that augmented levels of CXCR2 ligands are important in the recruitment of neutrophils during the pathogenesis of inflammatory diseases and suggest that the interaction between CXCR2 ligands and CXCR2 may be pivotal in the recruitment of neutrophils to the lung during dsRNA-induced lung injury.

Based on these findings, we performed proof of principle studies *in vivo* using an antibody-mediated neutralization strategy to evaluate the direct role for CXCL1 and CXCL2/3 ligands and their interaction with CXCR2 during the pathogenesis of dsRNA-induced lung injury. The anti-CXCR2 Ab-treated mice demonstrated significant reductions specific to neutrophil infiltration that were paralleled by a decrease in lung injury. This suggests that if other leukocytes are recruited there are redundant pathways involved in their recruitment that are CXCR2-independent. Our findings are similar to previous neutralization studies in virus-infected mice that showed functional antagonism to the chemokine receptor CCR1 reduced mortality [49]. Our study is the first to demonstrate that neutralization of CXCR2 results in decreased neutrophil recruitment and lung injury induced by intratracheal dsRNA.

TLR3 is a pattern-recognition cell surface receptor that is responsible for specifically recognizing extracellular dsRNA [52]. It is a member of a family of toll-like receptors (TLRs) that aid the host in combating infections when microbial pathogens bind to their specific toll-like receptor to trigger NF $\kappa$ B and downstream generation of cytokines and costimulatory molecules during the innate immune attack. TLR3 thus plays an important role in host defense against viral infections. Our study showed that dsRNA treatment induced the expression of TLR3 on the cell surface of airways as compared to ssRNA-treated control animals. The upregulation of TLR3 in dsRNA-exposed mouse airways suggests a positive feedback system in which epithelial cells exposed to dsRNA increase

TLR3 expression on their cell surface. A similar upregulation of TLR3 has previously been described in epithelial cells *in vitro* treated with Respiratory syncytial virus (RSV)[53]. These findings are also consistent with *in vivo* studies using monoclonal antibody to TLR3 and genetic knockout mice of TLR3 [52,54] that establish the role of TLR3 in dsRNA recognition and raise the interesting possibility that TLR3 may be involved in the signaling pathway mediating dsRNA induction of CXC chemokines.

## Conclusion

In conclusion, we have demonstrated that the biological axis of CXCR2 ligand/CXCR2 signaling plays a pivotal role in mediating neutrophil recruitment and dsRNA-induced lung injury. This mechanism may be critical for the promotion of further lung injury and remodeling in patients who eventually develop chronic lung diseases such as asthma, COPD, cystic fibrosis, pulmonary fibrosis or bronchopulmonary dysplasia. The findings of the current study support the contention that CXCR2 ligands and CXCR2 mediate dsRNA-induced lung injury, and may be a therapeutic target to attenuate this pathology.

## Competing interests

The author(s) declare that they have no competing interests.

## Authors' Contributions

VL designed and carried out all experiments and drafted the manuscript; JB and MK contributed to analysis and interpretation of data; MB and YX contributed to performing animal experiments; and RS provided final analysis and interpretation of data.

## Acknowledgements

This work was supported in part by the National Institutes of Health (NIH), grants HL66027 and P50HL67665 (to R.S.), National Research Service Award (NRSA) Institutional Training Grant, T32 HD07549 (to V.L.) and the NIH-sponsored UCLA Child Health Research Career Development K12 Award (CHRCDA) (to V.L.).

## References

1. Hogg JC: **Role of latent viral infections in chronic obstructive pulmonary disease and asthma.** *Am J Respir Crit Care Med* 2001, **164**:S71-5.
2. Cheung OY, Chan JW, Ng CK, Koo CK: **The spectrum of pathological changes in severe acute respiratory syndrome (SARS).** *Histopathology* 2004, **45**:119-124.
3. Gern JE, Busse WW: **The role of viral infections in the natural history of asthma.** *J Allergy Clin Immunol* 2000, **106**:201-212.
4. Gern JE: **Viral respiratory infection and the link to asthma.** *Pediatr Infect Dis J* 2004, **23**:S78-86.
5. Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, Cherniack RM, Rogers RM, Sciurba FC, Coxson HO, Pare PD: **The nature of small-airway obstruction in chronic obstructive pulmonary disease.** *N Engl J Med* 2004, **350**:2645-2653.
6. Hogg JC: **The adenovirus and bronchopulmonary dysplasia: an association that could be causal or coincidental.** *Pediatr Res* 2000, **47**:175-176.
7. Courouclis XI, Welty SE, Ramsay PL, Wearden ME, Fuentes-Garcia FJ, Ni J, Jacobs TN, Towbin JA, Bowles NE: **Detection of microorgan-**

- isms in the tracheal aspirates of preterm infants by polymerase chain reaction: association of adenovirus infection with bronchopulmonary dysplasia. *Pediatr Res* 2000, **47**:225-232.
8. Wat D, Doull I: **Respiratory virus infections in cystic fibrosis.** *Paediatr Respir Rev* 2003, **4**:172-177.
  9. Lok SS, Egan JJ: **Viruses and idiopathic pulmonary fibrosis.** *Monaldi Arch Chest Dis* 2000, **55**:146-150.
  10. Tang YW, Johnson JE, Browning PJ, Cruz-Gervis RA, Davis A, Graham BS, Brigham KL, Oates JA, Loyd JE, Stecenko AA: **Herpesvirus DNA is consistently detected in lungs of patients with idiopathic pulmonary fibrosis.** *J Clin Microbiol* 2003, **41**:2633-2640.
  11. Subauste MC, Jacoby DB, Richards SM, Proud D: **Infection of a human respiratory epithelial cell line with rhinovirus. Induction of cytokine release and modulation of susceptibility to infection by cytokine exposure.** *J Clin Invest* 1995, **96**:549-557.
  12. Schroth MK, Grimm E, Frindt P, Galagan DM, Konno SI, Love R, Gern JE: **Rhinovirus replication causes RANTES production in primary bronchial epithelial cells.** *Am J Respir Cell Mol Biol* 1999, **20**:1220-1228.
  13. Majde JA: **Viral double-stranded RNA, cytokines, and the flu.** *J Interferon Cytokine Res* 2000, **20**:259-272.
  14. Jacobs BL, Langland JO: **When two strands are better than one: the mediators and modulators of the cellular responses to double-stranded RNA.** *Virology* 1996, **219**:339-349.
  15. Gern JE, Vrtis R, Grindle KA, Swenson C, Busse WW: **Relationship of upper and lower airway cytokines to outcome of experimental rhinovirus infection.** *Am J Respir Crit Care Med* 2000, **162**:2226-2231.
  16. Gern JE, French DA, Grindle KA, Brockman-Schneider RA, Konno SI, Busse WW: **Double-stranded RNA induces the synthesis of specific chemokines by bronchial epithelial cells.** *Am J Respir Cell Mol Biol* 2002.
  17. Guha-Thakurta N, Majde JA: **Early induction of proinflammatory cytokine and type I interferon mRNAs following Newcastle disease virus, poly [rI:rC], or low-dose LPS challenge of the mouse.** *J Interferon Cytokine Res* 1997, **17**:197-204.
  18. Bozic CR, Gerard NP, von Uexkull-Guldenband C, Kolakowski LFJ, Conklyn MJ, Breslow R, Showell HJ, Gerard C: **The murine interleukin 8 type B receptor homologue and its ligands. Expression and biological characterization.** *J Biol Chem* 1994, **269**:29355-29358.
  19. Lee J, Cacalano G, Camerato T, Toy K, Moore MW, Wood WI: **Chemokine binding and activities mediated by the mouse IL-8 receptor.** *J Immunol* 1995, **155**:2158-2164.
  20. Cerretti DP, Nelson N, Kozlosky CJ, Morrissey PJ, Copeland NG, Gilbert DJ, Jenkins NA, Dosick JK, Mock BA: **The murine homologue of the human interleukin-8 receptor type B maps near the lty-Lsh-Bcg disease resistance locus.** *Genomics* 1993, **18**:410-413.
  21. Harada A, Kuno K, Nomura H, Mukaida N, Murakami S, Matsushima K: **Cloning of a cDNA encoding a mouse homolog of the interleukin-8 receptor.** *Gene* 1994, **142**:297-300.
  22. Barnes PJ: **Potential novel therapies for chronic obstructive pulmonary disease.** *Novartis Found Symp* 2001, **234**:255-67; discussion 267-72.
  23. Gordon JR, Swystun VA, Li F, Zhang X, Davis BE, Hull P, Cockcroft DW: **Regular salbutamol use increases CXCL8 responses in asthma: relationship to the eosinophil response.** *Eur Respir J* 2003, **22**:118-126.
  24. Mehrad B, Strieter RM, Moore TA, Tsai WC, Lira SA, Standiford TJ: **CXC chemokine receptor-2 ligands are necessary components of neutrophil-mediated host defense in invasive pulmonary aspergillosis.** *J Immunol* 1999, **163**:6086-6094.
  25. Moore TA, Newstead MW, Strieter RM, Mehrad B, Beaman BL, Standiford TJ: **Bacterial clearance and survival are dependent on CXC chemokine receptor-2 ligands in a murine model of pulmonary Nocardia asteroides infection.** *J Immunol* 2000, **164**:908-915.
  26. Tsai WC, Strieter RM, Mehrad B, Newstead MW, Zeng X, Standiford TJ: **CXC chemokine receptor CXCR2 is essential for protective innate host response in murine Pseudomonas aeruginosa pneumonia.** *Infect Immun* 2000, **68**:4289-4296.
  27. Greenberger MJ, Strieter RM, Kunkel SL, Danforth JM, Laichalk LL, McGillicuddy DC, Standiford TJ: **Neutralization of macrophage inflammatory protein-2 attenuates neutrophil recruitment and bacterial clearance in murine Klebsiella pneumonia.** *J Infect Dis* 1996, **173**:159-165.
  28. Huffnagle GB, Strieter RM, Standiford TJ, McDonald RA, Burdick MD, Kunkel SL, Toews GB: **The role of monocyte chemotactic protein-1 (MCP-1) in the recruitment of monocytes and CD4+ T cells during a pulmonary Cryptococcus neoformans infection.** *J Immunol* 1995, **155**:4790-4797.
  29. Huffnagle GB, Strieter RM, McNeil LK, McDonald RA, Burdick MD, Kunkel SL, Toews GB: **Macrophage inflammatory protein-1alpha (MIP-1alpha) is required for the efferent phase of pulmonary cell-mediated immunity to a Cryptococcus neoformans infection.** *J Immunol* 1997, **159**:318-327.
  30. Keane MP, Belperio JA, Moore TA, Moore BB, Arenberg DA, Smith RE, Burdick MD, Kunkel SL, Strieter RM: **Neutralization of the CXC chemokine, macrophage inflammatory protein-2, attenuates bleomycin-induced pulmonary fibrosis.** *J Immunol* 1999, **162**:5511-5518.
  31. Belperio JA, Burdick MD, Keane MP, Xue YY, Lynch JP, Daugherty BL, Kunkel SL, Strieter RM: **The role of the CC chemokine, RANTES, in acute lung allograft rejection.** *J Immunol* 2000, **165**:461-472.
  32. Olszyna DP, Florquin S, Sewnath M, Branger J, Speelman P, van Deventer SJ, Strieter RM, van der Poll T: **CXC chemokine receptor 2 contributes to host defense in murine urinary tract infection.** *J Infect Dis* 2001, **184**:301-307.
  33. Belperio JA, Dy M, Burdick MD, Xue YY, Li K, Elias JA, Keane MP: **Interaction of IL-13 and C10 in the pathogenesis of bleomycin-induced pulmonary fibrosis.** *Am J Respir Cell Mol Biol* 2002, **27**:419-427.
  34. Huang M, Sharma S, Zhu LX, Keane MP, Luo J, Zhang L, Burdick MD, Lin YQ, Dohadwala M, Gardner B, Batra RK, Strieter RM, Dubinett SM: **IL-7 inhibits fibroblast TGF-beta production and signaling in pulmonary fibrosis.** *J Clin Invest* 2002, **109**:931-937.
  35. Keane MP, Belperio JA, Burdick MD, Strieter RM: **IL-12 attenuates bleomycin-induced pulmonary fibrosis.** *Am J Physiol Lung Cell Mol Physiol* 2001, **281**:L92-7.
  36. Keane MP, Belperio JA, Arenberg DA, Burdick MD, Xu ZJ, Xue YY, Strieter RM: **IFN-gamma-inducible protein-10 attenuates bleomycin-induced pulmonary fibrosis via inhibition of angiogenesis.** *J Immunol* 1999, **163**:5686-5692.
  37. Garcia-Ramallo E, Marques T, Prats N, Beleta J, Kunkel SL, Godessart N: **Resident cell chemokine expression serves as the major mechanism for leukocyte recruitment during local inflammation.** *J Immunol* 2002, **169**:6467-6473.
  38. Laichalk LL, Kunkel SL, Strieter RM, Danforth JM, Bailie MB, Standiford TJ: **Tumor necrosis factor mediates lung antibacterial host defense in murine Klebsiella pneumonia.** *Infect Immun* 1996, **64**:5211-5218.
  39. Arenberg DA, Kunkel SL, Poverini PJ, Glass M, Burdick MD, Strieter RM: **Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice.** *J Clin Invest* 1996, **97**:2792-2802.
  40. Belperio JA, Keane MP, Burdick MD, Londhe V, Xue YY, Li K, Phillips RJ, Strieter RM: **Critical role for CXCR2 and CXCR2 ligands during the pathogenesis of ventilator-induced lung injury.** *J Clin Invest* 2002, **110**:1703-1716.
  41. Sue RD, Belperio JA, Burdick MD, Murray LA, Xue YY, Dy MC, Kwon JJ, Keane MP, Strieter RM: **CXCR2 is critical to hyperoxia-induced lung injury.** *J Immunol* 2004, **172**:3860-3868.
  42. Green TP, Johnson DE, Marchessault RP, Gatto CW: **Transvascular flux and tissue accrual of Evans blue: effects of endotoxin and histamine.** *J Lab Clin Med* 1988, **111**:173-183.
  43. Saria A, Lundberg JM: **Evans blue fluorescence: quantitative and morphological evaluation of vascular permeability in animal tissues.** *J Neurosci Methods* 1983, **8**:41-49.
  44. Vassallo R: **Viral-induced inflammation in interstitial lung diseases.** *Semin Respir Infect* 2003, **18**:55-60.
  45. Weinberg JB, Lutzke ML, Alfinito R, Rochford R: **Mouse strain differences in the chemokine response to acute lung infection with a murine gammaherpesvirus.** *Viral Immunol* 2004, **17**:69-77.
  46. Weinberg JB, Lutzke ML, Efstathiou S, Kunkel SL, Rochford R: **Elevated chemokine responses are maintained in lungs after clearance of viral infection.** *J Virol* 2002, **76**:10518-10523.
  47. Kajon AE, Gigliotti AP, Harrod KS: **Acute inflammatory response and remodeling of airway epithelium after subspecies B1**



- human adenovirus infection of the mouse lower respiratory tract. *J Med Virol* 2003, **71**:233-244.**
48. Traynor TR, Majde JA, Bohnet SG, Krueger JM: **Intratracheal double-stranded RNA plus interferon-gamma: a model for analysis of the acute phase response to respiratory viral infections. *Life Sci* 2004, **74**:2563-2576.**
49. Bonville CA, Lau VK, DeLeon JM, Gao JL, Easton AJ, Rosenberg HF, Domachowske JB: **Functional antagonism of chemokine receptor CCR1 reduces mortality in acute pneumovirus infection in vivo. *J Virol* 2004, **78**:7984-7989.**
50. Zare F, Bokarewa M, Nenonen N, Bergstrom T, Alexopoulou L, Flavell RA, Tarkowski A: **Arthritogenic properties of double-stranded (viral) RNA. *J Immunol* 2004, **172**:5656-5663.**
51. Auten RL, Richardson RM, White JR, Mason SN, Vozzelli MA, Whorton MH: **Nonpeptide CXCR2 antagonist prevents neutrophil accumulation in hyperoxia-exposed newborn rats. *J Pharmacol Exp Ther* 2001, **299**:90-95.**
52. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA: **Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. *Nature* 2001, **413**:732-738.**
53. Rudd BD, Burstein E, Duckett CS, Li X, Lukacs NW: **Differential Role for TLR3 in Respiratory Syncytial Virus-Induced Chemokine Expression. *J Virol* 2005, **79**:3350-3357.**
54. Matsumoto M, Kikkawa S, Kohase M, Miyake K, Seya T: **Establishment of a monoclonal antibody against human Toll-like receptor 3 that blocks double-stranded RNA-mediated signaling. *Biochem Biophys Res Commun* 2002, **293**:1364-1369.**

Publish with **BioMed Central** and every scientist can read your work free of charge

*"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."*

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:  
[http://www.biomedcentral.com/info/publishing\\_adv.asp](http://www.biomedcentral.com/info/publishing_adv.asp)

